Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome.

Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome were investigated. Eighty patients with metabolic syndrome treated in Linyi Central Hospital from January 2017 to December 2017 were selected and divided into control group (n=40) and observation group (n=40). Patients in control group were treated with regular therapy using the Western medicine and drugs, while those in observation group, based on the treatment in control group, were treated with berberine. Changes in relevant indexes to blood glucose and lipid metabolisms and inflammatory factors were compared between the two groups. The correlation of inflammatory factor with fasting blood glucose, insulin resistance, triglyceride and total cholesterol was analyzed. At 1 month after treatment, levels of fasting blood glucose, 2 h postprandial blood glucose, insulin resistance index and blood lipid indexes in both groups were lower than those at 1 week after treatment (P<0.05). At 1 month after treatment, levels of fasting blood glucose, 2 h postprandial blood glucose, insulin resistance index and blood lipid indexes in observation group were significantly lower than those in control group during the same period (P<0.05). Moreover, levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in both groups at 1 month after treatment were lower than those at 1 week after treatment (P<0.05), and they were lower in observation group at 1 month after treatment than those in control group during the same period (P<0.05). Finally, hs-CRP was positively correlated with fasting blood glucose, insulin resistance, total cholesterol and triglyceride. The combined application of berberine in patients with metabolic syndrome can effectively regulate blood glucose and blood lipid of patients, alleviate insulin resistance and reduce the level of inflammatory response in the body.

Mangiferin inhibits hippocampal NLRP3 inflammasome and exerts antidepressant effects in a chronic mild stress mice model.

A growing body of evidence suggests that inflammation may contribute toward the development of major depressive disorder. Mangiferin, a glucosylxanthone from Mangifera indica, exerts a number of biological actions, including anti-inflammatory effects. Although mangiferin has potential antidepressant activity, the mechanisms of this effect remain unclear. The present study investigated the effects of mangiferin on behavioral changes and inflammatory responses induced by chronic mild stress (CMS) in mice. We found that treatment with mangiferin for 3 weeks significantly increased the body weight of mice and ameliorated CMS-induced behavioral abnormalities by increasing sucrose consumption, improving locomotor activities, and decreasing the immobility time in the forced-swimming test and tail-suspension test. It also suppressed increased serum corticosterone levels in CMS mice. In response to CMS induction, the NLR family, pyrin domain containing 3 (NLRP3) inflammasome was activated and interleukin (IL)-1ß and IL-18 levels were increased in the mouse hippocampus. Mangiferin treatment downregulated the expression of NLRP3, the adaptor protein ASC, and caspase-1, which subsequently reduced the production of IL-1ß and IL-18 in CMS mice. In sum, our results indicate that mangiferin exerts antidepressant-like effects in CMS model, possibly by inhibiting IL-1ß production and NLRP3 inflammasome expression.